AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas

Phosphoinositide-3-kinase (PI3K)-α inhibitors have shown clinical activity in squamous carcinoma (SCC) of head and neck (H&N) bearing PIK3CA mutations or amplification. Studying models of therapeutic resistance we have observed that SCCs cells that become refractory to PI3Kα inhibition maintain...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Cell
Autors principals: Elkabets, Moshe, Pazarentzos, Evangelos, Juric, Dejan, Sheng, Qing, Pelossof, Raphael A., Brook, Samuel, Benzaken, Ana Oaknin, Rodon, Jordi, Morse, Natasha, Yan, Jenny Jiacheng, Liu, Manway, Das, Rita, Chen, Yan, Tam, Angela, Wang, Huiqin, Liang, Jinsheng, Gurski, Joseph M., Kerr, Darcy A., Rosell, Rafael, Teixidó, Cristina, Huang, Alan, Ghossein, Ronald A., Rosen, Neal, Bivona, Trever G., Scaltriti, Maurizio, Baselga, José
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4398915/
https://ncbi.nlm.nih.gov/pubmed/25873175
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2015.03.010
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars